



**Contact:** Mark Geisberg  
**Location:** Monrovia, CA, USA  
**Email:** mgeisberg@silverlakeresearch.com  
**Tel:** 626.359.8441  
**Website:** www.silverlakeresearch.com



## Company Overview

**Industry Sector:** Diagnostics

**Company Overview:** Silver Lake Research Corporation (SLRC) has developed a proprietary system, called **EAP™** (*Enhanced Affinity Platform*), capable of producing high affinity, high-specificity monoclonal antibodies to a wide range of difficult targets. Using these unique EAP-derived antibodies, SLRC has invented proprietary immunoassay test kit formats, maximizing the sensitivity and specificity of detection for many priority targets. Today, SLRC continues to develop new immunoassay test kits for our own product lines and for our partners, capitalizing on the powerful combination of EAP-derived antibodies and patented formats.

**Target Market(s):** Consumer products, clinical diagnostics, environmental and food safety diagnostics, research reagents.

## Management

### Leadership:

Mark Geisberg, Ph.D., Founder and CEO  
 Robert DiNello, Ph.D., VP Test Kit Development  
 Tom Round, VP Business Development

### Scientific Collaborators:

Ann Stapleton, MD, Professor, Department of Medicine, University of Washington, Seattle, WA  
 Lee Riley, Ph.D., Professor of Infectious Disease, School of Public Health, UC Berkeley

Keywords: Clinical diagnostics, urinary tract infection, UTI, infectious disease testing, lateral flow assay, EAP System

## Key Value Drivers

**Technology\*:** SLRC is developing the first rapid, point-of-care diagnostic test for Urinary Tract Infections, one of the most common infectious diseases in the developed world. This test kit, based on proprietary monoclonal antibodies and patented test formats, will allow the confirmation of UTI in a doctor's office, avoiding the current practice of "empirical diagnosis".

**Competitive Advantage:** SLRC's test kit is a 10-minute, CLIA-waived POU/POC diagnostic with comparable accuracy to urine culture, the current gold-standard diagnostic. Because urine culture entails a 48-hr turnaround, and because other rapid tests are notoriously inaccurate, current medical practice relies on "empirical diagnosis" based on symptoms - with a high rate of variability and misdiagnosis. Professional societies have repeatedly stressed the need for a rapid UTI diagnostic test, which will be made possible by SLRC's antibodies and immunoassay formats.

**Plan & Strategy:** seeking a commercialization partner

\*Technology funded by NIDDK and being commercialized under the NIH-CAP

## Product Development

